Sterile Injectable Contract Manufacturing Market Size Worth USD 68.05 Billion by 2034 | CAGR: 12.2%

The global sterile injectable contract manufacturing market size is expected to reach USD 68.05 billion by 2034, according to a new study by Polaris Market Research. The report “Sterile Injectable Contract Manufacturing Market Size, Share, Trends, Industry Analysis Report: By Molecule Type (Small Molecules and Large Molecules), By Product Type, By Service Type, By Therapeutic Application, By Route of Administration, By End Use, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The sterile injectable contract manufacturing market has seen significant growth in recent years, driven by the rising demand for biologics and complex pharmaceutical formulations. Advanced delivery systems and high-quality injectables are now a necessity in the rapidly changing medical industry. Injectable drugs cover an extensive portfolio of medicines that can be administered through injections and are used in multiple applications, such as cancer, diabetes, and vaccines. Injectables have become more popular because of the quick effects that they can bring as well as the preference towards minimally invasive treatments. The industry includes a varied group of contract manufacturers who specialize in such services as formulation development, fill-finish, and packaging.

One of the key factors contributing to the growth of this market is the rising prevalence of chronic diseases and the increasing aging population, which demands innovative treatment solutions. Conditions such as cancer, autoimmune disorders, and infectious diseases often require injectable therapies. This increases the need for sterile injectables. Additionally, the surge in demand for personalized medicine and biologics has prompted pharmaceutical companies to seek contract manufacturing organizations (CMOs) that specialize in the production of these complex formulations.

Sterile Injectable Contract Manufacturing Market Report Highlights

• North America held the largest revenue share of 36.15%in 2025. This is due to robust pharmaceutical infrastructure in the region.
• The market in Asia Pacific is estimated to register a significant CAGR of 13.75%. This is owing to the increasing investments in healthcare infrastructure and a rising population.
• The small molecules segment is expected to experience substantial growth at an 10.15% CAGR. This is owing to the ongoing research and development activities focused on new therapies. 
• The oncology segment led with an 29.15% sterile injectable contract manufacturing market share in 2025. The segment’s leading position is driven by the high prevalence of cancer globally.
• The CNS diseases segment is projected to grow at a 14.15% CAGR. This is owing to the rising prevalence of neurological disorders.
• A few of the key market players include Aenova Group; Alcami Corporation; Boehringer Ingelheim BioXcellence; Cipla Limited; CordenPharma International; Delpharm; FAMAR Health Care Services; Fresenius Kabi AG; Jubilant HollisterStier; NextPharma Technologies; PCI Pharma Services; Pfizer CentreOne; Recipharm AB; Simtra BioPharma Solutions; Unither Pharmaceuticals; Vetter Pharma-Fertigung GmbH & Co. KG; and WuXi Biologics.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Sterile Injectable Contract Manufacturing Market Report

Polaris Market Research has segmented the sterile injectable contract manufacturing market report on the basis of molecule type, product type, service type, therapeutic application, route of administration, end use, and region:

By Molecule Type Outlook (Revenue, USD Billion, 2021–2034)

• Small Molecules
• Large Molecules

By Product Type Outlook (Revenue, USD Billion, 2021–2034)

• API
• Finished Drug Product
  • Vials
  • Prefilled Syringes
  • Ampoules
  • Specialty Injectables

By Service Type Outlook (Revenue, USD Billion, 2021–2034)

• Clinical Trial Manufacturing
• Commercial Manufacturing
• Aseptic Fill-Finish
• Packaging & Labelling

By Therapeutic Application Outlook (Revenue, USD Billion, 2021–2034)

• Oncology
• Diabetes
• Cardiovascular
• CNS Diseases
• Infectious Disorders
• Musculoskeletal
• Anti-Viral

By Route of Administration Outlook (Revenue, USD Billion, 2021–2034)

• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)

By End Use Outlook (Revenue, USD Billion, 2021–2034)

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others

By Region Outlook (Revenue, USD Billion, 2021–2034)

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • Indonesia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa